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“There is no such thing as absolute value in this world. You can only estimate 
what a thing is worth to you.” 
 
Charles Dudley Warner (1829-1900) 
American essayist and novelist 
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Abstract 
Introduction: There is a high prevalence of drug-related problems (DRPs) in 
community-dwelling residents which results in increased morbidity, mortality and 
healthcare expenditure. The Australian government has reimbursed pharmacists to 
identify and prevent or resolve DRPs through Home Medicines Reviews (HMRs) in 
these patients since 2001. Funding for the HMR program was based on studies 
undertaken prior to its implementation that indicated HMRs would be cost-effective 
due to reductions in drug costs and health service utilisation. Since the introduction of 
the program, there has been limited Australian research into the economic outcomes 
of HMRs. Furthermore, the results of international studies have questioned the clinical 
and cost-effectiveness of pharmacist-led medication reviews. The overall aim of the 
research described in this thesis was to investigate the clinical and cost-effectiveness 
of HMRs. To achieve this aim, the following objectives were formulated and 
addressed: 
 to investigate novel methods for assessing the clinical and cost-effectiveness of 
HMRs; 
 to investigate the characteristics of the DRPs identified in HMRs, including the 
drugs and conditions involved, and the recommendations made to resolve or 
prevent DRPs; 
 to estimate the clinical effectiveness and cost-effectiveness of HMRs; and 
 to investigate potential avenues to optimise the clinical effectiveness and cost-
effectiveness of HMRs. 
Method: A methodology that used expert opinion to predict the outcomes of HMRs 
was developed, based on previous research of interventions undertaken in 
community pharmacies. The development of this methodology necessitated two 
studies to be undertaken whereby the healthcare system costs and quality of life 
effects of numerous common clinical conditions resulting from medication use were 
estimated using a combination of expert opinion and literature values. 
To evaluate HMRs, an observational cohort study was conducted across all states in 
Australia. Pharmacists accredited to perform HMRs submitted a random sample of 
HMRs that they had undertaken in 2008. Information from the HMR referral, report 
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and outcomes of the HMR were classified according to standardised systems and 
entered into an electronic database for analysis. A panel of experts reviewed a sample 
of the HMRs and estimated the clinical outcomes of the recommendations made in the 
HMRs. A cost-consequence and cost-utility analysis was performed to evaluate the 
cost-effectiveness of HMRs from an Australian government perspective.  
A sub-study was undertaken that investigated the relationship between cost-effective 
HMRs and factors that prior research suggested may influence the cost-effectiveness 
of HMRs. 
Results: A “consequences table” was developed whereby estimates of healthcare 
system costs and quality of life effects of 51 common clinical consequences were 
evaluated at three levels of severity. The estimates of these parameters appeared to be 
plausible and reasonable, and demonstrated moderate to high validity and reliability 
where testing was possible.  
Six hundred and sixty-one HMRs were submitted by one hundred and forty-nine 
pharmacists. The HMR reports documented 2323 DRPs, of which the most common 
were Condition not adequately treated (16.5% of DRPs), Therapy required (11.3%) and 
Toxicity evident (10.6%). The most common DRP was inadequate pain management 
which was identified in 118 (17.9%) patients. The drug groups most commonly 
involved in DRPs were antithrombotics, peptic ulcer and oesophageal reflux therapies, 
and lipid modifying agents.  
The pharmacists made 2727 recommendations to resolve the DRPs. The most 
frequently made recommendations included performing laboratory monitoring, 
commencing a new medication, or ceasing another. Information relating to the 
outcomes of the recommendations made to resolve the DRPs was available for 66% of 
the data (1801 recommendations). Of these recommendations, 1565 (87%) required 
the prescriber to act on the recommendations to implement them. Approximately 
three quarters of the DRPs documented in the HMRs were potentially resolved or 
managed. 
On average, each HMR was estimated to result in a saving to the health system of 
$85.79, which was insufficient to offset the cost of the HMR ($323.80). Savings 
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resulted from predicted reductions in health resource utilisation (general practitioner 
and specialist visits, medical investigations and hospitalisations (P<0.001)). A trend in 
reduced drug costs was also observed (P=0.070). Significant reductions in the risk of 
arrhythmias, confusion and myopathy were predicted to occur as a result of the HMRs 
(P<0.001).  Quality of life was estimated to improve minimally (0.001 QALYs per 
patient, P<0.001), and the cost per QALY gained (incremental cost-effectiveness ratio) 
was $177 566. Extensive sensitivity analysis was undertaken, which indicated 
minimal likelihood that HMRs were cost-effective using a threshold of $50 000 per 
QALY. A majority of the potential savings to the healthcare system occurred in a small 
number of HMRs. 
A sub-study of the factors associated with cost-effective HMRs identified that the 
pharmacists who had performed cost-effective HMRs had undertaken more 
continuing-education (P=0.006) and performed more HMRs in total (P=0.041) than 
the pharmacists who had not performed cost-effective HMRs. A greater proportion of 
HMR referrals that contained recent and relevant pathology/ laboratory data resulted 
in cost-effective HMRs compared to referrals that did not (P=0.03). 
Limitations resulting primarily from the methodology employed to assess the HMRs 
may have resulted in the study underestimating the cost-effectiveness of HMRs. Had a 
longer time horizon than 12-months been used, then greater cost savings to the 
healthcare system and improvements in quality of life would have been realised. The 
inclusion of other costs to the healthcare system not considered in the study also may 
have resulted in HMRs demonstrating greater cost-effectiveness.  
Conclusion: DRPs are frequently identified and reported in HMRs. However, the 
economic and clinical benefits of addressing most of them are minor in the 12 months 
following the HMR. Future research should focus on the identification of predictors of 
cost-effective HMRs and increasing the uptake of HMRs using these factors if funding 
for the program is to continue. 
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